venBio Partners LLC Long-Term Concentrated

CIK: 0001776382 · Show all filings

Period: Q1 2021 (← Previous) (Next →)

Filing Date: May 17, 2021

Total Value ($000): $1,052,382 (100.0% shares, 0.0% debt)

Holdings (8)

ALXO ALX ONCOLOGY HLDGS INC 68.0%

Value ($000) $715,272 Shares 9,699,925 Est. Cost $39.31 Unrealized +100.2%

HRMY HARMONY BIOSCIENCES HLDGS IN 11.0%

Value ($000) $115,793 Shares 3,504,624 Est. Cost $36.46 Unrealized -3.8%

— AKERO THERAPEUTICS INC 6.7%

Value ($000) $70,909 Shares 2,444,311 Est. Cost $19.15 Unrealized —

PHVS PHARVARIS N V 6.1%

Value ($000) $64,447 Shares 2,303,310 Est. Cost $31.46 Unrealized 0.0%

— CHECKMATE PHARMACEUTICALS IN 4.2%

Value ($000) $44,595 Shares 3,673,374 Est. Cost $11.51 Unrealized —

APLS APELLIS PHARMACEUTICALS INC 2.0%

Value ($000) $21,046 Shares 490,471 Est. Cost $15.34 Unrealized +208.4%

— METACRINE INC 1.8%

Value ($000) $18,967 Shares 3,059,123 Est. Cost $10.21 Unrealized —

— VERONA PHARMA PLC 0.1%

Value ($000) $1,353 Shares 161,897 Est. Cost $9.65 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ALXO	ALX ONCOLOGY HLDGS INC	9,699,925	$715,272	68.0%	$39.31	+100.2%	COM	00166B105
HRMY	HARMONY BIOSCIENCES HLDGS IN	3,504,624	$115,793	11.0%	$36.46	-3.8%	COM	413197104
—	AKERO THERAPEUTICS INC	2,444,311	$70,909	6.7%	$19.15	—	COM	00973Y108
PHVS	PHARVARIS N V	2,303,310	$64,447	6.1%	$31.46	0.0%	COM	N69605108
—	CHECKMATE PHARMACEUTICALS IN	3,673,374	$44,595	4.2%	$11.51	—	COM	162818108
APLS	APELLIS PHARMACEUTICALS INC	490,471	$21,046	2.0%	$15.34	+208.4%	COM	03753U106
—	METACRINE INC	3,059,123	$18,967	1.8%	$10.21	—	COM	59101E103
—	VERONA PHARMA PLC	161,897	$1,353	0.1%	$9.65	—	SPONSORED ADS	925050106